Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 11, 2012, Pages 2094-2097

  Marblestone, Jeffrey G ^a   LaRocque, James P ^a   Mattern, Michael R ^a   Leach, Craig A ^a  

^a Progenra Inc   (United States)

Author keywords

Assay; Drug discovery; E3 ligase; MuRF1; TRIM25; Ubiquitin

Indexed keywords

POLYUBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; ASSAY; ENZYME ACTIVITY; MONITORING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; TANDEM UBIQUITIN BINDING ENTITY; UBIQUITINATION;

HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MUSCLE PROTEINS; POLYUBIQUITIN; PROTEIN BINDING; TANDEM REPEAT SEQUENCES; TRANSCRIPTION FACTORS; UBIQUITIN; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84867013301     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.06.013     Document Type: Article

References (17)

1. Hershko A., Ciechanover A. The ubiquitin-proteasome pathway. Annu. Rev. Biochem. 1998, 67:425-479.
2. Sun L., Chen Z.J. The novel functions of ubiquitination in signaling. Curr. Opin. Cell Biol. 2004, 16(2):119-126.
3. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001, 70:503-533.
4. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
5. Ciechanover A. The ubiquitin-proteasomal pathway: on protein death and cell life. EMBO J. 1998, 17(24):7151-7160.
6. Bross P.F., Kane R., Farrell A.T., Abraham S., Benson K., Brower M.E., Bradley S., Gobburu J.V., Goheer A., Lee S.L., Leighton J., Liang C.Y., Lostritto R.T., McGuinn W.D., Morse D.E., Rahman A., Rosario L.A., Verbois S.L., Williams G., Wang Y.C., Pazdur R. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 2004, 10(12 Pt 1):3954-3964.
7. Hjerpe R., Aillet F., Lopitz-Otsoa F., Lang V., England P., Rodriguez M.S. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 2009, 10(11):1250-1258.
8. Selvin P.R. The renaissance of fluorescence resonance energy transfer. Nat. Struct. Biol. 2000, 7(9):730-734.
9. Yabuki N., Watanabe S., Kudoh T., Nihira S., Miyamato C. Application of homogeneous time-resolved fluorescence (HTRFTM) to monitor poly-ubiquitination of wild-type p53. Comb. Chem. High Throughput Screen. 1999, 2(5):279-287.
10. Kane S.A., Fleener C.A., Zhang Y.S., Davis L.J., Musselman A.L., Huang P.S. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal. Biochem. 2000, 278(1):29-38.
11. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., DeChiara T.M., Stitt T.N., Yancopoulos G.D., Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294(5547):1704-1708.
12. Clarke B.A., Drujan D., Willis M.S., Murphy L.O., Corpina R.A., Burova E., Rakhilin S.V., Stitt T.N., Patterson C., Latres E., Glass D.J. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007, 6(5):376-385.
13. Inoue S., Orimo A., Hosoi T., Kondo S., Toyoshima H., Kondo T., Ikegami A., Ouchi Y., Orimo H., Muramatsu M. Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(23):11117-11121.
14. Horie K., Urano T., Ikeda K., Inoue S. Estrogen-responsive RING finger protein controls breast cancer growth. J. Steroid Biochem. Mol. Biol. 2003, 85(2-5):101-104.
15. Maniatis T., Fritsch E.F., Sambrook J. Molecular Cloning: A Laboratory Manual 1983, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
16. Marblestone J.G., Suresh Kumar K.G., Eddins M.J., Leach C.A., Sterner D.E., Mattern M.R., Nicholson B. Novel approach for characterizing ubiquitin E3 ligase function. J. Biomol. Screen. 2010, 15(10):1220-1228.
17. Srisawasdi P., Kroll M.H., Lolekha P.H. Advantages and disadvantages of serum cholesterol determination by the kinetic vs the end point method. Am. J. Clin. Pathol. 2007, 127(6):906-918.